S
Steven Brem
Researcher at University of Pennsylvania
Publications - 230
Citations - 13571
Steven Brem is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Angiogenesis. The author has an hindex of 47, co-authored 195 publications receiving 10740 citations. Previous affiliations of Steven Brem include Hospital of the University of Pennsylvania & Moffitt Cancer Center.
Papers
More filters
Journal ArticleDOI
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp,Roger Stupp,Roger Stupp,Sophie Taillibert,Sophie Taillibert,Andrew A. Kanner,William L. Read,William L. Read,David M. Steinberg,Benoit Lhermitte,Steven A. Toms,Ahmed Idbaih,Manmeet Ahluwalia,Karen Fink,Francesco Di Meco,Frank S. Lieberman,Jay-Jiguang Zhu,Jay-Jiguang Zhu,Giuseppe Stragliotto,David Tran,Steven Brem,Steven Brem,Andreas F. Hottinger,Eilon D. Kirson,Gitit Lavy-Shahaf,Uri Weinberg,Chae-Yong Kim,Sun Ha Paek,Garth Nicholas,Jordi Burna,H Hirte,Michael Weller,Yoram Palti,Monika E. Hegi,Zvi Ram +34 more
TL;DR: In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance Temozolmide alone, resulted in statistically significant improvement in progression-free survival and overall survival.
Journal ArticleDOI
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Henry Brem,Steven Piantadosi,Steven Piantadosi,Peter C. Burger,Michael D. Walker,Robert G. Selker,N. A. Vick,K Black,Michael B. Sisti,Steven Brem,G Mohr,P Muller,R Morawetz,S.C Schold +13 more
TL;DR: Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Journal ArticleDOI
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Donald M. O'Rourke,MacLean Nasrallah,Arati Desai,J. Joseph Melenhorst,Keith Mansfield,Jennifer J.D. Morrissette,Maria Martinez-Lage,Steven Brem,Eileen Maloney,Angela Shen,Randi Isaacs,Suyash Mohan,Gabriela Plesa,Simon F. Lacey,Jean-Marc Navenot,Zhaohui Zheng,Bruce L. Levine,Hideho Okada,Carl H. June,Jennifer Brogdon,Marcela V. Maus +20 more
TL;DR: The initial experience with CAR T cells in recurrent GBM suggests that although intravenous infusion results in on-target activity in the brain, overcoming the adaptive changes in the local tumor microenvironment and addressing the antigen heterogeneity may improve the efficacy of EGFRvIII-directed strategies in GBM.
Journal ArticleDOI
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
Roger Stupp,Roger Stupp,Roger Stupp,S. Taillibert,S. Taillibert,Andrew A. Kanner,William L. Read,William L. Read,David M. Steinberg,Benoit Lhermitte,Steven A. Toms,Ahmed Idbaih,Manmeet Ahluwalia,Karen Fink,Francesco Di Meco,Frank S. Lieberman,Jay-Jiguang Zhu,Jay-Jiguang Zhu,Giuseppe Stragliotto,David Tran,Steven Brem,Andreas F. Hottinger,Eilon D. Kirson,Gitit Lavy-Shahaf,Uri Weinberg,Chae-Yong Kim,S. H. Paek,Garth Nicholas,Jordi Burna,Hal W. Hirte,Michael Weller,Yoram Palti,Monika E. Hegi,Zvi Ram +33 more
Journal ArticleDOI
Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End results (SEER) data, 1973-1991
TL;DR: Improvements in diagnostic and treatment procedures since the mid-1970s have resulted in improved survival rates for patients diagnosed as having medulloblastoma, oligodendroglioma, and astrocytoma, controlling for age at diagnosis.